Summary
RXRX Chart
People also search for
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and Sanofi, have delivered $500M+ in milestone payments, but further commercial validation is pending. The internal pipeline, led by REC-4881 for FAP, potentially lags competitors (more data is required) and is unlikely to generate significant revenue before 2030.
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down
Recursion misses Q2 earnings and revenue estimates as collaboration revenues fall year over year, sending shares lower while pipeline and partnership programs advanced.
Recursion Pharmaceuticals, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 210 | $859.81 | $666.75 | -$193.06 | -22.45% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 291,939 | $1.07M | $940,043.58 | -$131,376.43 | -12.26% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 2,053 | $10,760.23 | $6,877.55 | -$3,882.68 | -36.08% |
| NA Nizar Araji National Bank Of Canada /FI/ | 739,631 | $2.72M | $2.37M | -$341,001.8 | -12.56% |
| BG Bart Gancher Intech Investment Management LLC | 108,308 | $574,613.48 | $347,668.68 | -$226,944.8 | -39.5% |
Recursion Pharmaceuticals, Inc. (RXRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Recursion Pharmaceuticals, Inc. ever had a stock split?
Recursion Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Najat Khan CEO | NASDAQ (NGS) Exchange | 75629V104 CUSIP |
| US Country | 600 Employees | - Last Dividend | - Last Split | 16 Apr 2021 IPO Date |
Overview
Recursion Pharmaceuticals, Inc. is a pioneering clinical-stage biotechnology firm focused on revolutionizing the drug discovery process by leveraging an integration of technological advancements across various fields including biology, chemistry, automation, data science, and engineering. This innovative approach aims to industrialize and streamline the identification and development of novel therapeutic candidates. Founded in 2013 and based in Salt Lake City, Utah, Recursion Pharmaceuticals has established itself as a leader in utilizing technology to decode complex biological data, thereby accelerating the path from research to treatment. The company's diverse collaborative efforts include partnerships with major entities such as Bayer AG, the University of Utah Research Foundation, Ohio State Innovation Foundation, Roche & Genentech, and Takeda Pharmaceutical Company Limited, further underlining its commitment to advancing healthcare through scientific and technological excellence.
Products and Services
Recursion Pharmaceuticals operates at the forefront of drug discovery for various serious health conditions, advancing a portfolio that spans from clinical trials to preclinical stages. These include:
- REC-994: Currently in Phase 2 clinical trials, this drug candidate is being developed for the treatment of cerebral cavernous malformation, a condition characterized by blood vessel abnormalities in the brain.
- REC-2282: This drug is in Phase 2/3 clinical trials aiming to treat neurofibromatosis type 2, a disorder causing tumors to form on nerve tissue.
- REC-4881: In Phase 1b/2 clinical trial, REC-4881 is targeted to treat familial adenomatous polyposis, a hereditary condition that increases the risk of forming many polyps in the gastrointestinal tract, leading to cancer.
- REC-3964: Undergoing Phase 1 clinical trials, REC-3964 is focused on the treatment of Clostridioides difficile infection, a bacterial infection causing a range of symptoms from diarrhea to life-threatening inflammation of the colon.
- REC-4881 for AXIN1/APC Mutant Cancers: Also, REC-4881 is undergoing a separate Phase 2 clinical trial for the treatment of cancers with AXIN1 or APC mutations, spotlighting the drug's versatility in addressing different conditions.
- RBM39 for HR-Proficient Ovarian Cancer: In the preclinical stage, this product candidate aims to treat HR-proficient ovarian cancer, focusing on a subset of ovarian cancer patients with specific genetic markers.
